6533b871fe1ef96bd12d1188

RESEARCH PRODUCT

How pediatricians in Spain manage the first acute wheezing episode in an atopic infant. Results from the TRAP study.

A. Escribano MontanerJose A. Castro-rodriguezJ. Pellegrini BelinchonJ.j. Morell BernabéJ. Garde GardeLuis Garcia-marcos

subject

Pulmonary and Respiratory MedicineHypersensitivity ImmediateAllergyPediatricsmedicine.medical_specialtyImmunologyAdrenergic beta-AntagonistsAdministration OralPrimary carePediatricsMaintenance therapyAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsRecurrenceSurveys and QuestionnairesAdministration InhalationmedicineImmunology and AllergyHumansRespiratory soundsAnti-Asthmatic AgentsMetered Dose InhalersFamily historyPractice Patterns Physicians'AsthmaRespiratory Soundsmedicine.diagnostic_testBronchial Spasmbusiness.industryInhalerData CollectionMasksInfantGeneral Medicinemedicine.diseaseAsthmaSpainChild PreschoolOral steroidAcute DiseasePractice Guidelines as TopicDrug Therapy CombinationGuideline AdherencebusinessCase ManagementInhalation Spacers

description

Abstract Background Although the treatment of asthma has been addressed in several guidelines, the management of the first acute wheezing episode in infants has not often been evaluated. We surveyed practicing pediatricians in Spain about the treatment they would provide in a simulated case. Material and methods A random sample of 3000 pediatricians and physicians who normally treated children was surveyed. The questionnaire inquired about how they would treat a first mild-to-moderate wheezing attack in a 5-month-old boy with a personal and family history of allergy. Pediatricians were asked about their professional background. Results A total of 2347 questionnaires were returned with useful data (78.2 %). Most (90.4 %) of the pediatricians would use a short-acting beta2 - agonist (SABA) via a metered-dose inhaler with a spacer and a face mask or nebulizer. However, only 34.5 % chose a SABA alone: 31.3 % added an oral steroid and 27.6 % added an inhaled corticosteroid (ICS). The factors associated with the use of ICS in the acute attack were: (1) lack of specific training in pediatrics (OR 1.45; 1.12-1.85) and (2) primary care health center setting (OR 1.31; 1.01-1.69) or rural setting (OR 1.28; 1.01-1.66). Forty-four percent did not recommend any follow-up treatment while 20.7% prescribed ICS as maintenance therapy. The factors related to this decision were the same as those described above. Conclusions The management of a first wheezing episode seems to meet published guidelines among Spanish pediatricians with formal training in pediatrics and in those who work in a hospital setting or in urban areas.

10.1016/s0301-0546(05)73250-xhttps://pubmed.ncbi.nlm.nih.gov/16371214